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ABSTRACT: Variations in mitochondrial DNA (mtDNA)
cytochrome b (mt-cyb) are frequently found within the
healthy population, but also occur within a spectrum of
mitochondrial and common diseases. mt-cyb encodes the
core subunit (MT-CYB) of complex III, a central compo-
nent of the oxidative phosphorylation system that drives
cellular energy production and homeostasis. Despite sig-
nificant efforts, most mt-cyb variations identified are not
matched with corresponding biochemical data, so their
functional and pathogenic consequences in humans re-
main elusive. While human mtDNA is recalcitrant to
genetic manipulation, it is possible to introduce human-
associated point mutations into yeast mtDNA. Using this
system, we reveal direct links between humanmt-cyb vari-
ations in key catalytic domains of MT-CYB and significant
changes to complex III activity or drug sensitivity. Strik-
ingly, m.15257G>A (p.Asp171Asn) increased the sensi-
tivity of yeast to the antimalarial drug atovaquone, and
m.14798T>C (p.Phe18Leu) enhanced the sensitivity of
yeast to the antidepressant drug clomipramine.We demon-
strate that while a small number of mt-cyb variations had
no functional effect, others have the capacity to alter com-
plex III properties, suggesting they could play a wider role
in human health and disease than previously thought. This
compendium of new mt-cyb-biochemical relationships in
yeast provides a resource for future investigations in
humans.
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Introduction
Complex III (or bc1 complex) of the mitochondrial respiratory
chain is central to the cellular energy production process. The com-
plex is anchored within the inner mitochondrial membrane and
catalyzes the transfer of electrons from ubiquinol to cytochrome
c and couples this electron transfer to vectorial proton transloca-
tion across the inner mitochondrial membrane. The enzyme ex-
ists as a functional dimer, consisting of 10 or 11 polypeptides per
monomer. All of the subunits are encoded by the nuclear genome,
except cytochrome b (MT-CYB; MIM# 516020), which is encoded
by mitochondrial DNA (mtDNA). MT-CYB is predominantly a
hydrophobic protein consisting of eight transmembrane helices.
The subunit contains two hemes and forms the two ubiquinol and
inhibitor binding sites, called Qo and Qi sites (Fig. 1A). Complex
III is a main site of proton gradient generation, thus of energy con-
servation. It is also a main site of reactive oxygen species (ROS)
production. ROS are involved in signaling pathways that coordinate
both the nucleus and mitochondria to drive beneficial homeostatic
responses, but they can alsodamage cellular components that induce
cell death.
In the human population, the mt-cyb exhibits a high level of
variation. Over 410 missense changes from the Homo sapiensmito-
chondrion complete genome reference sequence (rCRS: GenBank
NC 012920.1) have been reported (http://mitomap.org) and 90 in
MSeqDR-LSDB (https://mseqdr.org/MITO/genes/MT-CYB), with
some overlap between the various databases.
While a number of these variations are likely to be silent, some
variations, especially those located in regions involved in the cat-
alytic activity and inhibitor binding, may induce subtle changes in
complex III function. Under exposure to inhibitors, to different en-
ergy substrates or to higher energy demands, the altered function
of the variant complex III might be revealed, which could affect
the fitness of cells and the health of the individuals bearing these
variants. Thus, what may have previously been considered a silent
variation, can, under different physiological circumstance, result in
a significant effect. Indeed, a recent analysis of 874 genes in 589,306
genomes identified 13 adults harboring highly penetrant mutations
that typically cause eight severe Mendelian conditions, with no
reported clinical manifestations [Chen et al., 2016], which further
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Figure 1. Thecatalytic core of yeast complex III.A: Redox active groupsare locatedwithin three subunits that form thecatalytic core: cytochrome
c1 (purple), the iron–sulfur protein/ISP (yellow), and cytochrome b (blue), which contains two b-type hemes (bl and bh) and forms the two quinol
binding sites: Qo (site of quinol oxidation), with bound stigmatellin (gray) and Qi (site of quinone reduction) with bound ubiquinone (green), located
on opposite sides of the membrane. During catalytic turnover, a quinol molecule binds at the Qo site is deprotonated, and transfers one electron
through the [2Fe-2S] cluster of the ISP and the c-type heme of cytochrome c1 to cytochrome c. Following a bifurcated pathway, a second electron
is transferred across the membrane to hemes bl and h and delivered to quinone bound at the Qi site, forming a stable semiquinone. A second quinol
oxidation event at the Qo site completes the Q-cycle with the formation of fully reduced quinol at the Qi site. In the overall reaction, two molecules
of quinol are oxidized to quinone at the Qo site and one molecule of quinone is reduced to quinol at the Qi site with the release of four protons
to the positive side of the membrane and the uptake of two protons from the matrix. The figure was drawn using the coordinates 2IBZ of yeast
complex III. B: Schematic presentation of cytochrome b and location of the residues of interest. The Qi region is in green; the Qo region is in gray.
The helices are marked by letter (A–H). The positions of the residues (human numbering) studied here are shown by orange dots.
suggests that “silent,”-“nonsilent” mutation paradigm is question-
able. Several studies have addressed thequestionof the consequences
ofmt-cyb variations at a population level. For example,m.15257G>A
that causes a D to N substitution at position 171 (p.Asp171Asn)
of the MT-CYB polypeptide [Heher and Johns, 1993; Johns and
Neufeld, 1993; Johns et al., 1993] is associated with Leber hereditary
optic neuropathy (LHON) and a number of different disease co-
horts, whereas m.14798T>C that causes a phenylalanine to leucine
amino acid substitution in MT-CYB (p.Phe18Leu) is frequently
found in patient-derived glioblastoma biopsy cells [Kirches et al.,
2001; Larman et al., 2012; Lloyd et al., 2015], but biochemical data
are often lacking. Obtaining such biochemical data is experimen-
tally challenging due to the absence of tools for introducing single
variations into mammalian mtDNA. This hiatus in these data could
either lead to potentially important mtDNA variations in health
and disease being incorrectly dismissed, or to finite resources being
erroneously diverted toward the investigation of those that are not
important.
Yeast (Saccharomyces cerevisiae) is a convenient model for the
study of point mutations in the core subunit of complex III. The
organism has well-known advantages. Cells can survive in the ab-
sence of respiration relying exclusively on fermentation as an energy
source. Therefore, the severe malfunction or even the absence of the
respiratory enzymes is not lethal. Yeast complex III, and especially
the catalytic core, is very similar to the mammalian enzyme, and
several atomic structures are available. Many genetic tools are well
developed. Of particular interest is the mitochondrial transforma-
tion technique by which chosen mutations can be introduced into
mitochondrially encoded genes, such asmt-cyb. So far, only S. cere-
visiae and the green alga Chlamydomonas reinhardtii are amenable
to mitochondrial transformation. Mitochondrial mutants can then
be analyzed by a broad range of biochemical/biophysical methods.
Using that approach, we have previously assessed the impact of
human disease mutations on complex III and used mutants with
severe respiratory function defect to explore possible compensation
mechanisms [Fisher et al., 2004a, 2004b; Meunier et al., 2012]. The
yeastmodel is also an easy-to-use tool for characterizing acquired re-
sistance mutations reported in mt-cyb of pathogens after treatment
by drugs targeting complex III or to explore the structural basis of
the natural differential sensitivity of complex III to inhibitors [Hill
et al., 2003; Song et al., 2015a, 2015b].
Here, taking advantage of the yeast model, we studied 22 single
human variations, including some with reported disease associa-
tions, to obtain biochemical informationon their functional impact.
We focused on monitoring the effect of mutations that cause non-
synonymous amino-acid substitutions located in, or in the vicinity
of, the MT-CYB catalytic/binding domains (Fig. 1B). In particular,
we tested the impact of frequent polymorphisms: (1) p.Phe18Leu
located in the Qi site on complex III sensitivity to the antidepression
compound clomipramine and (2) p.Asp171Asn, the signature of
haplogroup J, located nearby the Q0 site on the complex III sensi-
tivity to the antimalaria drug atovaquone.
We show that some variants previously reported as “silent”muta-
tions, including some frequentpolymorphisms, significantlymodify
the properties of the yeast complex III, suggesting they may play a
greater role in human health and disease than previously thought.
Materials and Methods
Data Collection
For each human mutation under investigation, information
on the prevalence and heteroplasmy level in normal/healthy
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and pathologic tissues was obtained from the following five
databases: MITOMAP (http://www.mitomap.org/MITOMAP),
HmtDB (http://www.hmtdb.uniba.it/hmdb/), mtDB (http://www.
mtdb.igp.uu.se/), and MSeqDR-LSDB (https://mseqdr.org/
MITO/genes/MT-CYB)) and an in-house glioblastoma (GBM)
database [Lloyd et al., 2015]. Known genotype–phenotype
correlations were explored using OMIM (http://www.omim.org/).
Media and Chemicals
The following media were used for the growth of yeast: YPD
(1% yeast extract, 2% peptone, 3% glucose), YPG (1% yeast extract,
2%peptone, 3%glycerol), YPEth (1%yeast extract, 2%peptone, 3%
ethanol), YPGal (1% yeast extract, 2% peptone, 0.1% glucose, 3%
galactose). Equine cytochrome c, decylubiquinone, atovaquone, and
clomipramine were purchased from Sigma–Aldrich Chimie, Lyon,
Rhone Alpes, France.
Generation of Yeast Cytochrome bMutants
The plasmid pBM5 carrying the wild-type intron-less sequence
of mt-cyb gene was constructed by blunt end cloning of mt-cyb
PCR product into the pCRscript vector (Agilent Technologies,
Les Ulis, Cedex, France). The mutagenesis was performed using
the Quickchange Site-Directed Mutagenesis Kit (Agilent Tech-
nologies) according to the manufacturer’s recommendations. After
verification of the sequence, the plasmids carrying the mutated
genes were used for biolistic transformation. The mitochondrial
transformation was performed by microprojectile bombardment
as described in Hill et al. (2003) and Meunier (2001). The
strains are identical except for the mutations introduced in mt-
cyb, and are all homoplasmic (i.e., they contain only one mtDNA
population).
Diploids were used in the experiments, except for monitoring
the sensitivity of respiratory growth to atovaquone, where the
AD1-9 series was used. AD1-9 strain harbors multiple deletions
in the ABC transporter genes that render the strain more sensitive
to drugs than standard yeast strains (α ura3 his1, yor1::hisG,
snq2::hisG, pdr5:: hisG, pdr10::hisG, pdr11::hisG,
ycf1::hisG, pdr3::hisG, pdr15::hisG, pdr1::hisG). We
previously found that while the yeast complex III is highly sensitive
to atovaquone, the drug cannot reach the complex unless ABC
transporters are deactivated [Hill et al., 2003].
Preparation of Mitochondria and Measurement
of Cytochrome c Reductase Activity
Yeast mitochondria were prepared as in Lemaire and Dujardin
(2008). Briefly, yeast grown in YPGal medium were harvested at
mid-log phase. Protoplasts were obtained by enzymatic digestion
of the cell wall using zymolyase in an osmotic protection buffer.
Mitochondria were then prepared by differential centrifugation fol-
lowing osmotic shock of the protoplasts. Mitochondrial samples
were aliquoted and stored at –80°C. Concentration of complex III
in the mitochondrial samples was determined from dithionite-
reduced optical spectra, using ε = 28.5 mM–1/cm at 562 – 575
nm. Decylubiquinol-cytochrome c reductase activities were deter-
mined at room temperature by measuring the reduction of cy-
tochrome c (final concentration of 20 μM) at 550 nm versus 540
nm over 1-min time course in 10 mM potassium phosphate pH 7,
0.01% (w/v) lauryl-maltoside and 1 mM KCN. Mitochondria were
added to obtain a final concentration of 5–30 nM of complex III.
Activity was initiated by the addition of decylubiquinol, a synthetic
analogue of ubiquinol (final concentration of 40 μM). Initial rates
were measured as a function of the decylubiquinol concentration.
Eachmeasurementwas repeated three times and the values obtained
were averaged. Activity (turnover) was estimated as cytochrome c
reduction rates per complex III.
Inhibitor Titration
Cytochrome c reduction activitywasmeasured as described above
in the presence of increasing concentrations of inhibitors (six to 10
different concentrations). Each measurement was repeated two or
three times and averaged. The midpoint inhibition concentrations
(IC50) were determined from the titrations and the IC50 values were
normalized by the concentration of complex III.
Respiratory Growth Assays
Yeast strains were grown in 5 ml of YPEth medium with in-
creasing concentration of drug. Cultures were inoculated from 1-
day-old cultures on YPG to an OD600 nm of 0.2 and incubated
at 28°C with vigorous shaking to maintain good aeration. Cell
densities measured as OD600 nm were estimated 2 or 3 days after
inoculation.
Results and Discussion
Spectrum of Human mt-cyb Variations Analyzed in Yeast
The 22 human polymorphisms chosen for analysis in yeast
are presented in Table 1. With the exception of one variation
(m.15048G>C), reported in a single GBM-patient [Lloyd et al.,
2015], all variations were reported as polymorphisms in one or
more of the mitochondrial databases. Eleven polymorphisms have
no known disease association:m.15122A>G, 15147C>T, 15171G>A,
15191T>A, 15258GA>AG, 15048G>C, 15404G>C, 15138A>G,
15152G>A, 15153G>A, and 15502C>G, and were rare, being found
in typically 10 cases or less in thenormal/healthy humanpopulation.
Nine polymorphisms had one or more reported disease associa-
tions: m.15140G>A, 15164T>C, 15257G>A, 15258A>G, 14798T>C,
14841A>G, 14858G>A, 15047G>A, and 15500G>A. The top three
most frequently recorded polymorphisms in normal healthy cases,
were also themost frequently recorded indisease-associated cases (in
descending order of patient frequency): m.14798T>C, 15257G>A,
and 15047G>A. The individual mt-cyb variations were associated
with one or more of the following type of disorders: cardiolog-
ical (e.g., cardiomyopathy and Noonan syndrome); neurological
(e.g., LHON, Parkinson’s and schizophrenia); metabolic (e.g., dia-
betes); and cancers (e.g., breast, thyroid, GBM, pituitary adenoma,
oral squamous cell carcinoma, and lung), there were no genotype–
phenotype correlations in the OMIM database, with the exception
of m.15257G>A, which is associated 9% of LHON cases [Heher and
Johns, 1993; Johns and Neufeld, 1993; Johns et al., 1993].
The polymorphisms were chosen on the basis of the location
of the residues in the structure of complex III. Nine variations (at
positions 126, 132, 134, 140, 142, 149, and 171) are located in or
nearby the Qo site. Eight variations (at positions 18, 32, 38, 101, and
220) are in or nearby the Qi site. Five variations (at positions 131,
136, and 252) are located in possible proton routes from the Qo site
(Table 1; Fig. 1B).
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Predicted effect on complex III (based on
yeast model and on structure)
Matching amino-acid
substitutionb
Qo domain: atovaquone sensitivity
m.15122A>G p.Thr126Ala 5 0 n/a None p.Thr127Ile
m.15140G>A p.Val132Ile 1 3 (breast and thyroid
cancer)
Slight modification of ato sensitivity CysCysVal133–135
ValLeuPro
m.15147C>T p.Pro134Leu n 0 n/a Slight modification of ato sensitivity
m.15164T>C p.Phe140Leu 6 1 (diabetes) Slight modification of ato sensitivity p.His141Tyr/Phe
m.15171G>A p.Gly142Glu 1 0 n/a Severely decreased activity, decreased ato
sensitivity
p.Gly143Ala
m.15191T>A p.Leu149Met 2 0 n/a Decreased ato sensitivity and activity p.Leu150Phe
p.Asp171 (rCRS) p.Ser172Asp
m.15257G>A p.Asp171Asn 319 (haplogroup J) 51c 100 (GBM) Increased sensitivity to ato p.Ser172Asn
m.15258A>G p.Asp171Gly 24 2 (diabetes
type2/LHON)
Increased sensitivity to ato p.Ser172Gly
m.15258GA>AG p.Asp171Ser n 0 n/a Increased sensitivity to ato p.Ser172 (wt)
Qi domain: clomipramine sensitivity
p.Phe18 (rCRS) p.Ile17Phe
m.14798T>C p.Phe18Leu 4,410 233d 99 (GBM) Increased sensitivity to clom p.Ile17 (wt)
m.14841A>G p.Asn32Ser 1 1 (LHON) Increased sensitivity to clom, decreased
activity
p.Asn31Ser
m.14858G>A p.Gly38Ser 10 2 (mental disorder,
diabetes)
Increased sensitivity to clom p.Gly37Ser
m.15048G>C p.Gly101Ala n 0 n/a None
m.15047G>A p.Gly101Ser 50 3 (thyroid cancer,
diabetes type II)
None
m.15048G>A p.Gly101Asp 0 1 (GBM) 17 (GBM) Decreased sensitivity to clom p.Gly100Asp
m.15404T>C
and 15406C>A
p.Phe220Leu 2 0 n/a Increased sensitivity to clom p.Phe225Leu
Qo domain: proton pathway
m.15138A>G p.Tyr131Cys n 0 n/a None or slightly decreased activity p.Tyr132Phe
m.15152G>A p.Gly136Ser 3 0 n/a Severely decreased activity p.Gly137Arg
m.15153G>A p.Gly136Asp 4 0 n/a Severely decreased activity p.Gly137Glu
p.Asp252(rCRS) p.His253Asp
m.15502C>G p.Asp252Glu 1 0 n/a None p.His253Glu
m.15500G>A p.Asp252Asn 1 2 (diabetes/GBM) 5 (GBM) None p.His253Asn
n, undetermined number of cases.
n/a, not applicable.
aNucleotide variations are relative to the Homo sapiensmitochondrion complete genome (GenBank NC_012920.1).
bMutations were introduced in yeast cytochrome b using the mitochondrial transformation technique (Materials and Methods) with the exception of G137E that had been
obtained by random mutagenesis.
cGBM, pituitary adenoma, Parkinson’s, CADASIL, Noonan syndrome, schizophrenia, LHON, oral squamous cell carcinoma, lung cancer.
dGBM, thyroid tumors, LHON, prostate cancer, type I endometrial carcinoma, schizophrenia, breast cancer, cardiomyopathy, optic atrophy, CPEO, pituitary adenoma, oral cavity
carcinoma, Warthin tumor, OXPHOS system deficiency, Noonan syndrome.
Mutations Within or Nearby the Qo Site Influence
Atovaquone Sensitivity
Atovaquone (used in combination with proguanil, and marketed
as Malarone R©) is a popular prophylactic drug that also shows high
efficiency in the treatmentofuncomplicatedPlasmodium falciparum
malaria. The compound is also used to treat Pneumocystis jirovecii
pneumonia,Toxoplasma gondii toxoplasmosis, and other infections.
Atovaquone inhibits complex III by binding in the Qo site, as re-
vealed by the resolution of the atomic structure of yeast complex III
with bound atovaquone (PDB code 4PD4) [Birth et al., 2014] and
by the Qo site location of point mutations found in the mt-cyb of
atovaquone-resistant parasites [Hill et al., 2003;Mather et al., 2005].
The complex III of the malaria parasite—and yeast—is highly
sensitive to atovaquone, whereas the mammalian complex III is
naturally more resistant to atovaquone, which is expected of an
antimalarial compound used to treat humans. The IC50 (midpoint
inhibition concentration) values per nM complex III were estimated
to be 75 and 4 nM for the bovine and the yeast enzymes, respectively
[Vallie`res et al., 2013].The IC50 value for themalaria parasite enzyme
was reported to be similar to the yeast value, around 3 nM [Biagini
et al., 2008]. The differential sensitivity between mammalian and
Plasmodium (and yeast) is likely to be due to amino-acid variations
in the Qo site, more specifically, variations ofMT-CYB residues 275,
278, and 295, as suggested by mutational analysis using the yeast
model [Vallie`res et al., 2013].
Nine of the chosen human polymorphisms (Table 1) are lo-
cated at seven positions in or near the atovaquone binding pocket,
and thus might modify the sensitivity of the enzyme to the drug
(Fig. 2). In order to explore this, we generated yeast mutants
harboring equivalent MT-CYB mutations and analyzed their
atovaquone sensitivity; we also reviewed previously published
data.
The human p.Gly142Glu (yeast p.Gly143) and p.Leu149Met
(yeast p.Leu150) (Table 1) are located in the atovaquone bind-
ing site (Fig. 2). We predict that these substitutions would alter
the sensitivity to atovaquone but also interfere with catalytic ac-
tivity, by hindering the correct binding of the substrate ubiquinol.
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Figure 2. Location of the residues in yeast Qo domainwith bound ato-
vaquone. Atovaquone (gray) is bound is a position similar to stigmatellin
(Fig. 1A). Heme bl is in red. Yeast numbering is used. Residues p.Gly143,
p.Leu150, p.Thr127, p.Cys133, p.Cys134, p.Val135, p.Thr136, p.His141, and
p.Ser172 are colored in yellow and their sidechains are shown. The
figure was drawn using the coordinates 4PD4 of yeast complex III.
In yeast, mutation p.Gly143Ala—a minor addition of a single car-
bon atom compared with the addition of a bulky acidic group in
p.Gly143Glu—confers a ninefold increase in atovaquone resistance
[Fisher andMeunier, 2005] (Supp. Table S1). p.Gly143Aspwas stud-
ied in a bacterial complex III and was shown to decrease enzymatic
activity severely [Daldal et al., 1989] (Supp. Table S1). It is likely that
in human complex III, p.Gly142Glu would also result in an inactive
enzyme. Mutation p.Leu149Met would have a less dramatic effect
on the enzyme activity. In yeast, mutation p.Leu150Phe results in a
threefold increase in atovaquone resistance with the loss of 50% of
complex III activity [Hill et al., 2003] (Supp. Table S1).
Human variants p.Val132Ile, p.Pro134Leu, and p.Phe140Leu (Ta-
ble 1) are located in the vicinity of the Qo pocket (residues 133, 135,
141 in yeast [Fig. 2]). We have previously observed that, in yeast,
atovaquone sensitivity was modified by mutations in the region
133–141 (Supp. Table S1). The residues are not in direct contact
with bound atovaquone in the crystal structure butmutations could
indirectly modify the binding pocket and, by consequence, slightly
alter the binding of the drug [Fisher and Meunier 2005; Vallie`res
et al., 2013]. p.Thr126Ala is located distal from the Qo binding
pocket. As expected, the matching yeast mutation p.Thr127Ile had
no effect on complex III activity and atovaquone sensitivity [Hill
et al., 2003] (Supp. Table S1).
We then sought to determine whether mutations of human
residue 171 (172 in yeast) (Table 1), also located in the vicinity
of the Qo site (Fig. 2), could modify the sensitivity to atovaquone.
The yeast residue, Ser172 (wt), which also reflects a rare poly-
morphism in humans, was replaced by Asp, the residue present
in the human reference sequence; Asn, the frequent polymor-
phism and marker of haplogroup J in humans; and finally Gly,
also a polymorphism in humans. Modified IC50 values to ato-
vaquone were observed (Fig. 3A). Complex III with p.Ser172Asp
was found to be more resistant (IC50 of 11.5) than the wt, Gly,
and Asn (IC50s of 7, 7.5, and 5, respectively) to atovaquone.
None of the mutations had a major effect on the catalytic ac-
tivity of the complex (Supp. Table S1). We then tested whether
these small changes in sensitivity could be observed when mon-
Figure 3. A: Atovaquone sensitivity of yeast mutant and wild-type
control complex III. IC50s, midpoint inhibition concentrations, were es-
timated from the titration measurements and reported per complex III
(Materials andMethods). Each measurement was repeated three times
and averaged. Error bars represent standard deviations. B and C: Sen-
sitivity of yeast mutant and wild-type control respiratory growth to ato-
vaquone. Atovaquone sensitivity is presented for each strain as the
percentage of growth relative to wild-type control, that is, untreated.
Each measurement was repeated at least twice and averaged. Error
bars represent standard deviations. B: Strain harboring single mutation
p.Ser172Asp, Asn, Gly and p.Leu150Phe. C: Strain with multiple changes
(HS) in the Qo site that replace yeast residues by human equivalents.
itoring the respiratory growth of mutants and control strains.
As shown in Figure 3B, p.Ser172Asn, p.Ser172Gly, and the wt
displayed an increased sensitivity compared with p.Ser172Asp (and
to p.Leu150Phe, mentioned above).
In order to confirm the differential sensitivity induced by the
polymorphisms at position 172, we tested whether the same be-
havior could be observed in mutant strains that harbor a complex
III Qo site that more closely resembled that of the human enzyme.
To this end, two strains were genetically constructed. In addition
to the amino acid substitution at position 172, eight mutations
in the Qo site were introduced by replacing the yeast residues by
their human equivalents: CysCysVal133–135 ValLeuPro, p.His141Phe,
p.Ley275Phe, p.Phe278Ala, and p.Met295Leu. The resulting
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Figure 4. A: Comparison of the yeast and mammalian Qi sites. Superposition of yeast (blue) and bovine (pink) cytochrome b structures. Ubiquinol
is in green and heme bh, in red. The figure was drawn using the coordinates 4PD4 and 1PP9 of yeast and bovine complex III, respectively. The two
structures were superposed using Chimera. Residues p.Ile17, p.Gly100, and p.Phe225 of yeast cytochrome b and p.Phe220, p.Gly101, and p.Phe220
of mammalian cytochrome b are shown. B: Possible interactions between p.Asn31 and helix E, and between p.Gly37Ser and ubiquinol. Cytochrome
b is colored in blue, ubiquinol in green, p.Asn31 and p.Ser37 in yellow, waters as black sticks, and heme bh in red. Possible hydrogen bonds are
indicated in black lines. Minimum distance between p.Ser37 and ubiquinol p.Cys13 hydrogen is 1.0 A˚. The structure was drawn using 2IBZ. In silico
mutation p.Gly37Ser was introduced using Chimera.
strains, calledHS-p.Ser172Asp andHS-p.Ser172Asn, were tested for
the sensitivity to atovaquone (Fig. 3C). Both strains were inhibited
at slightly higher doses of atovaquone than the control strain. This
was expected as we have previously observed that yeast to human
amino acid substitutions at positions 275, 278, and 295 resulted in
an increased resistance to the drug [Vallie`res et al., 2013]. Despite
this, HS-p.Ser172Asn was still more sensitive to atovaquone than
HS-p.Ser172Asp.
Mutations Within and Nearby the Qi Site Modify
Clomipramine Sensitivity
The main clinical use of clomipramine is as a tricyclic antide-
pressant, but it is also showing promise in preclinical studies for
the treatment of glioma, potentially via a mitochondrial targeted
mechanism. In addition to its mainmode of action, which is to bind
nonselectively to 5-hydroxytryptaimine and noradrenaline uptake
receptors, which endows it with antidepressant activity [Rang et al.,
2011], the drug has been shown to induce apoptosis in malignant
glioma via the direct release of cytochrome c that stimulates the
p-c-Jun pathway and triggers the caspase cascade [Levkovitz et al.,
2005; Pilkington et al., 2008]. Furthermore, clomipramine has been
shown to impair cell respiration and inhibit complex III in glioma,
thus implicating the complex III in the glioma cell killing effect of
this drug [Daley et al., 2005; Higgins and Pilkington, 2010].
We tested clomipramine inhibitory effect on the catalytic activity
of bovine and yeast complex III, using purified mitochondria, and
determined the IC50s. The drug was found to be a weak inhibitor of
the enzymes, with IC50 values of 24 ± 5 and 3.4 ± 0.1 μMper nM of
bovine and yeast complex, respectively. Bovine complex III seems,
thus, naturally less sensitive to clomipramine than the yeast enzyme.
Complex III possesses two distinct inhibitor binding sites, the Qo
(that binds atovaquone) and the Qi site. Comparisons of the bovine
and yeast Qi sites reveal structural differences that could be respon-
sible for the observed differential sensitivity to clomipramine, in
particular the replacement of p.Ile17 present in yeast by Phe present
Figure 5. Clomipramine sensitivity of yeastmutant andwild-type con-
trol complex III. IC50s, midpoint inhibition concentrations, were esti-
mated from the titration measurements and normalized for complex
III concentration (Materials and Methods). Each measurements was
repeated three times and averaged. Error bars represent standard de-
viations. IFGD: p.Ile17Phe+p.Gly100Asp.
in the mammalian enzyme (Fig. 4A). Intriguingly, we have pre-
viously identified a parallel amino acid substitution (p.Phe18Leu)
in 30% of biopsy-derived GBM samples, and predicted it to affect
complex III inhibitor binding [Lloyd et al., 2015].
We thus sought to determine whether variations in the Qi site
could influence sensitivity of complex III to clomipramine.
As shown inFigure 5, themutationp.Ile17Phe (replacing the yeast
amino acid by the human residue) resulted in a twofold decrease in
clomipramine sensitivity. Thus, the phenylalanine naturally present
at that position (p.Phe18) in mammalian MT-CYB could explain,
at least in part, the decreased clomipramine sensitivity of the mam-
malian enzyme comparedwith the yeast enzyme. The frequent poly-
morphism p.Phe18Leu in humans corresponding to yeast wild-type
p.Ile17 is likely to result in an increase sensitivity to the drug.
Other mutations in or in the vicinity of the Qi site were also
investigated: p.Asn31Ser (p.Asn32Ser and rare polymorphism in
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Figure 6. A: Complex III activity in wild-type control and mutants. The ubiquinol cytochrome c reductase assays were performed as described in
Materials and Methods. The activities measured at saturated substrate concentrations (40 mM decylubiquinol) were reported relative to complex
III concentration. The measurements were repeated at least twice and averaged. The error bars represent standard deviations. B: Respiratory
growth of wild-type control and mutants. Serial dilutions in water of cells pregrown on glucose plates were spotted on plates containing either
glucose (YPD, fermentative medium) or glycerol (YPG, respiratory medium) and incubated for two (YPD) to 4 days (YPG) at 28°C.
humans), p.Gly37Ser (p.Gly38Ser and a rare polymorphism in
humans) (Fig. 4B), p.Gly100Asp (p.Gly101Asp reported in a
GBM-patient) [Lloyd et al., 2015], and p.Phe225Leu (struc-
turally similar to p.Phe220Leu in humans, rare polymorphism).
p.Gly100Asp resulted in decreased clomipramine sensitivity,
whereas p.Asn31Ser, p.Gly37Ser, and p.Phe225Leu increased the
sensitivity to the drug (Fig. 5). Interestingly, the double mutation
p.Ile17Phe-p.Gly100Asp had an additive effect, further decreasing
clomipramine sensitivity. These data substantiate the hypothesis
that Qi site is a clomipramine target and Qi site mutations can af-
fect clomipramine sensitivity. None of these mutations had a major
impact on complex III activity, except p.Asn31Ser that resulted in a
twofold decrease: its activity was 25 ± 0.8 sec–1 compared with 56 ±
4.6 sec–1 for the wild type (Supp. Table S1).
The examination of the structure of the Qi pocket domain (Fig.
4A) showed that replacement of the small residue p.Ile17 by a
bulky phenylalanine (p.Ile17Phe) could sterically hinder the bind-
ing of clomipramine, which is a far larger molecule than the natu-
ral ligand, whereas the substitution of F225 by the smaller leucine
(p.Phe225Leu) would leave more space for the binding of the drug.
The effect of p.Gly100Asp is less straightforward to explain as the
residue is not located directly inQi site. However, the replacement of
the small glycineby thebigger andchargedaspartatemight indirectly
alter the pocket reducing its affinity for the drug. Thatmajor change
(p.Gly100Asp) had minimal effect on the catalytic activity of the
complex III. As the enzyme seems to accommodate p.Gly100Asp,
it is likely that the less drastic substitutions reported in humans,
p.Gly101Ala and p.Gly101Ser, would also have minimal impact on
the enzyme properties.
The increased clomipramine sensitivity induced by p.Asn31Ser
and p.Gly37Ser might be caused by modifications of the binding
pocket (Fig. 4B). As we have previously reported, the equivalent
residue to p.Asp31 in human (p.Asp32) participates in stabilizing
hydrogen bonds with key residues in the Qi site [Lloyd and McGee-
han, 2013]. The introduction of a serine might slightly modify the
local structure, which would stabilize clomipramine but decrease
the catalytic activity. A serine at position 37 might slightly tighten
the drug binding without impairing the activity.
Qo Proton PathwayMutations Influence Complex III Activity
As explained in Figure 1, during the catalytic reaction, a quinol is
oxidized in the Qo site. Upon oxidation, two protons are released in
the solvent phase at the intermembrane side of the innermembrane.
Several residues and water molecules are likely to form pathways for
proton movement [Hunte et al., 2003; Palsdottir et al., 2003]. The
conserved residue p.Glu272 seems to be one of the main actors in
the proton relay [Wenz et al., 2006; Seddiki et al., 2008; Crofts et al.,
2013]. P.His253 and p.Tyr132 also interact with water molecules
and might be involved in forming proton routes. P.Gly137, in con-
tact with the conserved p.Ser140, is located in the vicinity of this
water-polar residue network (Supp. Fig. S1). We hypothesize that
mutation of these residues could impair the proton movement and
by consequence the catalytic activity of complex III.
In order to test this hypothesis systematically, we replaced
p.His253 in yeast by Asp (human rCRS), Glu (reported as a poly-
morphism), and Asn (reported polymorphism and in GBM) (Ta-
ble 1). His, Asp, Glu, and Asn are polar residues. In parallel, we
tested the effect of introducing the apolar residue Phe at that po-
sition, even though that mutation has not been observed in hu-
mans.We also assessed the effect of replacing the polar residue Y132
by the apolar Phe. Two other mutations were tested, p.Gly137Glu
and p.Gly137Arg, corresponding to the human polymorphisms,
p.Gly136Asp and p.Gly136Ser. We measured the complex III
activity and monitored the respiratory growth of the yeast mutants
(Fig. 6).
Replacement of p.His253 by Phe decreased the electron trans-
fer activity of the complex by 40% (Fig. 6A). The introduction of
the human residues Asp, Glu, or Asn resulted in a complex with a
higher electron transfer activity (130%–160% of the control activ-
ity). The introduction of an apolar residue at position 253 probably
slows down proton movement and concomitant electron transfer.
Asp, Glu, or Asn might facilitate the proton translocation and thus
increase the electron transfer rate. In organisms with a nonpro-
tonable residue at position 272, a glutamate at position equivalent
to p.His253 was observed, suggesting a role in proton movement
[Brasseur et al., 2002].
Themutationsofp.His253hadnoeffect on the respiratory growth
competence (Fig. 6B). The substitution p.Tyr132Phe had a more
severe impact and decreased complex III activity by around 50%
(Fig. 6A) resulting in a lower respiratory growth competence (Fig.
6B). The apolar residuePhe is likely to disrupt thewater network and
proton routes. Examination of the structure suggests that a polar
residue is required at that position. Thus, the replacement of the
tyrosine by a cysteine (human polymorphism p.Tyr131Cys) might
have only a mild effect.
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In contrast to p.Tyr131Cys, the human polymorphisms
p.Gly136Ser and particularly p.Gly136Asp (Table 1) are expected
to have dramatic effects. In yeast, the equivalent mutations
p.Gly137Arg and p.Gly137Glu caused, respectively, 70% and 90%
decrease in complex III activity and a very severe respiratory growth
defect (Fig. 6). The introduction of charged or polar residues at
that position could severely impair the transfer of protons from the
Qo site toward the negative side of the membrane, as previously
suggested [Tron and Lemesle-Meunier, 1990; Bruel et al., 1995].
Clinical Relevance and Future Prospects
The continual advancement of sequencing technologies has al-
lowed the identification of increasing numbers ofmt-cyb variations
in humans. However, it remains impossible to introduce single mu-
tations into human mtDNA and thus observe any direct genotype–
phenotype correlations at the molecular or cellular level. Although
the technology exists to produce custom cybrids, such cell lines are
likely to contain several mtDNA variations that could contribute
to phenotype [Singh et al., 2014]. Also, the process of creating cy-
brids can introduce irreversible epigenetic changes [Smiraglia et al.,
2008], as well as nuclear genome instability and mutation [Singh
et al., 2005], further confounding isolating a single mtDNA mu-
tation as contributing factor. Also, under normal circumstances,
subtle changes in complex III properties might be missed, and it
is only when cells are forced to use alternative metabolic pathways
through changes in their cellular environment, or in the presence of
inhibitors, as we have shown here, that they are revealed.
Our focus was to use the yeast model system, whose mtDNA
is amenable to genetic manipulation, to investigate the di-
rect functional consequences of human MT-CYB mutations on
corresponding complex III properties. Our results reveal that most
of the mutations that cause amino-acid replacements in key cat-
alytic regions of MT-CYB affected the sensitivity of complex III to
drugs and/or complex III activity. Although theMT-CYBmutations
investigated here could exert a more severe effect in yeast cells than
in human cells where they might be present at lower heteroplasmy,
the potential clinical relevance of the mutations to humans and
recommendations for future work are discussed below.
In this study, we showed seven amino-acid replacements in-
creased the sensitivity of yeast complex III to either atovaquone
or clomipramine (mutations corresponding to the human poly-
morphisms p.Asp171Asn, p.Asp171Gly, p.Asp171Ser, p.Phe18Leu,
p.Asn32Ser, p.Gly38Ser, and p.Phe220Leu). This is particularly sig-
nificant finding for p.Asp171Asn and p.Phe18Leu, as they frequently
occur in thenormal/healthy individuals, aswell as thosewithdisease.
p.Asp171Asn and p.Phe18Leu carriers (along with carriers of the
other rarer polymorphisms) might respond more strongly to ato-
vaquone and clomipramine, respectively: their complex III would
be inhibited at lower doses than the enzyme of controls, which
could lead to respiratory chain defect and impaired metabolism,
especially in cells that heavily rely on the respiratory chain for their
energy supply. Thus, the polymorphisms would be disadvantageous
for individuals/patients who are prescribed the drugs for the treat-
ment of malaria/depression, due to the potential side effects. Such
side effects are likely to be even more marked in individuals that
already harbor mitochondrial/metabolic disorders. The converse
would be expected for individuals carrying the rarer polymorphisms
that decrease atovaquone/clomipramine sensitivity. As new Qo and
Qi site inhibitors arebeingdevelopedas antimalarial agents [Doggett
et al., 2012; Nilsen et al., 2013; Stickles et al., 2015], it would seem
pertinent to determine their selectivity and efficacy on
p.Asp171Asn- or p.Phe18Leu-carrying human cells.
While enhanced sensitivity of complex III to atovaquone or
clomipramine may be a disadvantage for individuals carrying the
polymorphism p.Asp171Asn or p.Phe18Leu, it might be an advan-
tageous phenomenon for the selective killing of cancer cells, for ex-
ample, glioma, in which p.Asp171Asn and p.Phe18Leu are reported.
Further investigation into the role of mitochondrial genetic back-
ground in governing the potential selectivity/efficacy of chemother-
apeutic strategies that target complex III on human cancer cells is
therefore warranted. For example, the presence of p.Asp171Asn or
p.Phe18Leu could be used as an inclusion criterion for preclinical
trials testing either atovaquone or clomipramine on human can-
cer cells or in rodent models. Retrospective analyses could then be
conducted to determine whether p.Asp171Asn/p.Phe18Leu carriers
responded better to treatment than those that did not carry the
mutation.
Also in this study, we identified three amino-acid replacements
that severely decreased complex III activity, namely, p.Gly136Ser,
p.Gly136Asp, and p.Gly142Glu. These mutations, due to their im-
pact on yeast or bacterial complex III, are expected to be severely
pathological in humans. This could explain why they are rarely
detected in the human population. The few normal, healthy indi-
viduals that harbor these mutations could be examples of so-called
“resilient” individuals that despite possessing mutations for severe
Mendelian conditions, have no reported clinical manifestations of
the indicated disease [Chen et al., 2016]. Samples from these pa-
tients could be of interest to scientists who are seeking to discover
genetic and environmental modulators that buffer the effects of, in
this case, potentially deleterious mitochondrial mutations.
Other mutations (p.Asn32Ser and p.Leu149Met) would result in
a milder effect on complex III activity, which could still impact the
overall activity of the respiratory chain. These mutations might also
be pathogenic, as previously predicted for p.Asn32Ser, a LHON-
associated mutation [Lloyd and McGeehan, 2013].
Finally, several substitutions are not expected to impair com-
plex III activity and are unlikely to be pathogenic: p.Phe18Leu,
p.Gly38Ser, p.Gly101Ala, p.Gly101Ser, p.Gly101Asp, p.Thr126Ala,
p.Asp171Asn, p.Asp171Gly, p.Asp171Ser, p.Phe220Leu,
p.Asp252Glu, and p.Asp252Asn. This is interesting because
the frequently occurring polymorphisms p.Asp171Asn and
p.Phe18Leu have been proposed to have a pathogenic role in
numerous diseases. Through association, p.Asp171Asn has been
proposed to cause one of the mildest LHON phenotypes, where
patients have difficulty in perceiving hand motion [Johns et al.,
1993]. However, results presented here from yeast cells suggest
that p.Asp171Asn is unlikely to contribute to LHON in isolation
and possibly other co-occurring mutations, either alone or in
combination with p.Asp171Asn, are more likely to be respon-
sible, as suggested previously [Mackey et al., 1996]. Similarly,
through association, p.Phe18Leu (and the rarer p.Gly101Asp and
p.Asp252Asn) has been proposed to contribute to several diseases,
including GBM [Lloyd et al., 2015]. Results presented here in yeast
cells suggest p.Phe18Leu and the other mutations are unlikely to be
responsible, but could play a role in clomipramine sensitivity.
We show that several human-associated mutations, when intro-
duced into yeast mtDNA, affect complex III activity and/or drug
sensitivity, with no clear relationship between the two parame-
ters. These findings suggest that while complex III mutations could
play a greater role in human health and disease than previously
thought, they also highlight once again the challenges associated
with predicting the functional importance of amino-acid substitu-
tions inMT-CYB, presumably due to the complicated cross-talk that
exists between mitochondrial function and the cellular environ-
ment. However, the yeast model system provides the opportunity to
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probe such relations in an uncomplicated genetic background un-
der different physiological conditions, including in the presence of
inhibitors. This compendium of new mt-cyb biochemical relation-
ships in yeast presented herewill help clinicians and scientists decide
which variations to prioritize for future preclinical investigations in
humans.
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